Cape Investment Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cape Investment Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$840	Hold	14	–	–	﹤0.01%	1376
2026 Q2	$801	Buy	+14	New	+$767	﹤0.01%	1362
2026 Q1	–	Sell	-23	Closed	-$1.37K	–	335
2025 Q4	$1.37K	Hold	23	–	–	﹤0.01%	1153
2025 Q3	$1.25K	Sell	23 -4	-15%	-$229	﹤0.01%	725
2025 Q2	$1.48K	Sell	27 -2	-7%	-$118	﹤0.01%	989
2025 Q1	$2.05K	Buy	29 +27	+1,350%	+$1.82K	﹤0.01%	889
2024 Q4	$131	Sell	2 -40	-95%	-$2.68K	﹤0.01%	1073
2024 Q3	$2.95K	Hold	42	–	–	﹤0.01%	784
2024 Q2	$3.46K	Sell	42 -136	-76%	-$11.3K	﹤0.01%	729
2024 Q1	$15.5K	Hold	178	–	–	0.01%	473
2023 Q4	$17.2K	Buy	178 +20	+13%	+$1.77K	0.01%	565
2023 Q3	$14K	Hold	158	–	–	0.01%	508
2023 Q2	$13.7K	Buy	158 +55	+53%	+$5.18K	0.01%	498
2023 Q1	$10K	Buy	+103	New	+$10.7K	0.01%	540

Other funds holding BMRN

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Cape Investment Advisory's BMRN Position: Q3 2026 in Review

Cape Investment Advisory held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 14 shares worth $840. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Cape Investment Advisory first reported a position in BMRN in Q1 2023 and has held it in 14 quarters since. The position peaked at $17.2K in Q4 2023. 25 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Cape Investment Advisory held 14 shares of BioMarin Pharmaceuticals worth $840 as of Q3 2026.
Cape Investment Advisory left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q3 2026, its #1376 holding.
Cape Investment Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Cape Investment Advisory's BioMarin Pharmaceuticals position peaked at $17.2K in Q4 2023.
25 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Cape Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.